Compare PRFX & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRFX | PPCB |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | Israel | Australia |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.8M |
| IPO Year | 2020 | 2011 |
| Metric | PRFX | PPCB |
|---|---|---|
| Price | $1.05 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 171.8K | 137.1K |
| Earning Date | 03-26-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.06 |
| 52 Week High | $5.39 | $9.36 |
| Indicator | PRFX | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 46.76 |
| Support Level | $0.97 | $0.15 |
| Resistance Level | $1.25 | $1.26 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 20.15 | 42.31 |
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.